Trial Profile
A 16-Week, Open-Label, Multicentre, Randomised, Parallel Study to Evaluate Efficacy and Safety of Repaglinide and Metformin Combination Therapy Compared to Repaglinide Monotherapy in Chinese OAD Naive Type 2 Diabetic Patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Repaglinide/metformin (Primary) ; Repaglinide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 24 Sep 2010 Results were presented at the 46th Annual Meeting of the European Association for the Study of Diabetes.
- 19 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Nov 2009 Actual patient number (433) added as reported by ClinicalTrials.gov.